CLAIMS

1. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the volume of menstrual blood loss in a female human patient, wherein the compound is to be administered to the patient in an amount of about 100 mg per day.

2. The use of claim 1, wherein the patient has uterine fibroids.

3. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating uterine fibroids in a female human patient, wherein the compound is to be administered to the patient in an amount of about 100 mg per day.

4. The use of any one of claims 1-3, wherein the compound is to be administered to the patient in the form of a pharmaceutically acceptable salt thereof.

5. The use of any one of claims 1-3, wherein the compound is to be administered to the patient in the form of a choline salt thereof.

6. The use of any one of claims 1-3, wherein the compound is to be administered to the patient orally.

7. The use of any one of claims 1-3, wherein the compound is to be administered to the patient once daily.

8. A kit comprising a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, wherein the compound is present in the kit in a unit dosage form comprising about 100 mg of the compound, and wherein the kit further comprises a package insert that instructs a user of the kit to administer the compound to a female human patient having uterine fibroids in an amount of about 100 mg per day.

9. The kit of claim 8, wherein the compound is present in the kit in the form of a pharmaceutically acceptable salt thereof.

10. The kit of claim 9, wherein the pharmaceutically acceptable salt is a choline salt.

11. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the volume of menstrual blood loss in a female

human patient, wherein the compound is to be administered to the patient in an amount of about 200 mg per day.

12. The use of claim 11, wherein the patient has uterine fibroids.

13. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating uterine fibroids in a female human patient in need thereof, wherein the compound is to be administered to the patient in an amount of about 200 mg per day.

14. The use of any one of claims 11-13, wherein the compound is to be administered to the patient in the form of a pharmaceutically acceptable salt thereof.

15. The use of any one of claims 11-13, wherein the compound is to be administered to the patient in the form of a choline salt thereof.

16. The use of any one of claims 11-13, wherein the compound is to be administered to the patient orally.

17. The use of any one of claims 11-13, wherein the compound is to be administered to the patient once daily.

18. The use of any one of claims 11-13, wherein the patient is to be further administered add-back therapy.

19. The use of claim 18, wherein the add-back therapy is to be administered to the patient once daily.

20. The use of claim 18, wherein the add-back therapy comprises an estrogen.

21. The use of claim 20, wherein the estrogen is β17-estradiol.

22. The use of claim 21, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day.

23. The use of claim 21, wherein the β17-estradiol is to be administered to the patient in an amount of about 0.5 mg per day.

24. The use of any one of claims 21-23, wherein the β17-estradiol is to be administered to the patient orally.

25. The use of claim 18, wherein the add-back therapy comprises a progestin.

26. The use of claim 25, wherein the progestin is norethindrone acetate.

27. The use of claim 26, wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

28. The use of claim 27, wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.1 mg per day.

29. The use of any one of claims 26-28, wherein the norethindrone acetate is to be administered to the patient orally.

30. The use of claim 18, wherein the add-back therapy comprises β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

31. The use of claim 18, wherein the add-back therapy comprises β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 0.5 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.1 mg per day.

32. A kit comprising a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, wherein the compound is present in the kit in a unit dosage form comprising about 200 mg of the compound, and wherein the kit further comprises a package insert that instructs a user of the kit to administer the compound to a female human patient having uterine fibroids in an amount of about 200 mg per day.

33. The kit of claim 32, wherein the compound is present in the kit in the form of a pharmaceutically acceptable salt thereof.

34. The kit of claim 33, wherein the pharmaceutically acceptable salt is a choline salt.

35. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the volume of menstrual blood loss in a female human patient, wherein the patient is to be administered add-back therapy comprising β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

36. The use of claim 35, wherein the patient has uterine fibroids.

37. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating uterine fibroids in a female human patient in need thereof, wherein the patient is to be administered add-back therapy comprising β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

38. The use of any one of claims 35-37, wherein the compound is to be administered to the patient in the form of a pharmaceutically acceptable salt thereof.

39. The use of any one of claims 35-37, wherein the compound is to be administered to the patient in the form of a choline salt thereof.

40. The use of any one of claims 35-37, wherein the compound is to be administered to the patient orally.

41. The use of any one of claims 35-37, wherein the compound is to be administered to the patient in an amount of about 200 mg per day.

42. The use of any one of claims 35-37, wherein the compound is to be administered to the patient once daily.

43. The use of any one of claims 35-37, wherein the add-back therapy is to be administered to the patient once daily.

44. The use of any one of claims 35-37, wherein the β17-estradiol is to be administered to the patient orally.

45. The use of any one of claims 35-37, wherein the norethindrone acetate is to be administered to the patient orally.